Chemomab Therapeutics Ltd
CMMB1.890USD
-0.030-1.56%
收盘 12/19, 16:00（美东）报价延迟15分钟
46.53M总市值
亏损市盈率 TTM
关于 Chemomab Therapeutics Ltd 公司
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Ltd简介
公司代码CMMB
公司名称Chemomab Therapeutics Ltd
上市日期Aug 14, 2012
CEOMor (Adi)
员工数量16
证券类型Depository Receipt
年结日Aug 14
公司地址Kiryat Atidim, Building 7
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Israel
邮编6158002
电话972773310156
网址https://www.chemomab.com/
公司代码CMMB
上市日期Aug 14, 2012
CEOMor (Adi)
Chemomab Therapeutics Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-82.96%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-82.96%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月18日 周二
更新时间: 11月18日 周二
持股股东
股东类型
持股股东
持股股东
占比
Otto (Erik)
6.86%
Apeiron Investment Group Ltd
4.60%
Rivendell Investments 2017-9 LLC
4.50%
Sphera Funds Management Ltd.
2.92%
Morgan Stanley & Co. LLC
1.46%
其他
79.66%
持股股东
持股股东
占比
Otto (Erik)
6.86%
Apeiron Investment Group Ltd
4.60%
Rivendell Investments 2017-9 LLC
4.50%
Sphera Funds Management Ltd.
2.92%
Morgan Stanley & Co. LLC
1.46%
其他
79.66%
股东类型
持股股东
占比
Individual Investor
9.55%
Family Office
4.60%
Corporation
4.50%
Hedge Fund
3.78%
Research Firm
1.91%
Investment Advisor/Hedge Fund
0.50%
Investment Advisor
0.16%
其他
75.00%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
30
390.31K
17.98%
--
2025Q3
30
390.31K
17.98%
-667.39K
2025Q2
30
1.06M
18.61%
+124.78K
2025Q1
31
932.92K
24.29%
-212.50K
2024Q4
32
1.04M
26.27%
-97.26K
2024Q3
29
1.14M
22.64%
+165.56K
2024Q2
28
668.24K
21.48%
+2.79K
2024Q1
32
666.14K
22.68%
-139.12K
2023Q4
33
705.36K
20.90%
+69.50K
2023Q3
33
635.85K
25.86%
-196.00
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Otto (Erik)
422.50K
8.17%
+133.75K
+46.32%
Aug 11, 2025
Apeiron Investment Group Ltd
283.00K
5.47%
+101.21K
+55.68%
Dec 31, 2024
Rivendell Investments 2017-9 LLC
277.13K
5.36%
--
--
Dec 31, 2024
Sphera Funds Management Ltd.
184.51K
3.57%
-40.59K
-18.03%
Jun 30, 2025
Morgan Stanley & Co. LLC
403.53K
7.8%
+374.24K
+1277.72%
Jun 30, 2025
Mor George (Adi)
79.27K
1.53%
--
--
Dec 31, 2024
Ikarian Capital LLC
53.26K
1.03%
--
--
Jun 30, 2025
George (Kobi)
50.06K
0.97%
-12.73K
-20.27%
Dec 31, 2024
Cohen (Neil Harris)
35.30K
0.68%
-2.50K
-6.61%
Dec 31, 2024
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 08, 2025
Merger
4→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
公告日期
类型
比率
Aug 08, 2025
Merger
4→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
常见问题
Chemomab Therapeutics Ltd的前五大股东是谁？
Chemomab Therapeutics Ltd 的前五大股东如下：
Otto (Erik)持有股份：422.50K，占总股份比例：8.17%。
Apeiron Investment Group Ltd持有股份：283.00K，占总股份比例：5.47%。
Rivendell Investments 2017-9 LLC持有股份：277.13K，占总股份比例：5.36%。
Sphera Funds Management Ltd.持有股份：184.51K，占总股份比例：3.57%。
Morgan Stanley & Co. LLC持有股份：403.53K，占总股份比例：7.80%。
Otto (Erik)持有股份：422.50K，占总股份比例：8.17%。
Apeiron Investment Group Ltd持有股份：283.00K，占总股份比例：5.47%。
Rivendell Investments 2017-9 LLC持有股份：277.13K，占总股份比例：5.36%。
Sphera Funds Management Ltd.持有股份：184.51K，占总股份比例：3.57%。
Morgan Stanley & Co. LLC持有股份：403.53K，占总股份比例：7.80%。
Chemomab Therapeutics Ltd的前三大股东类型是什么？
Chemomab Therapeutics Ltd 的前三大股东类型分别是：
Otto (Erik)
Apeiron Investment Group Ltd
Rivendell Investments 2017-9 LLC
Otto (Erik)
Apeiron Investment Group Ltd
Rivendell Investments 2017-9 LLC
有多少机构持有Chemomab Therapeutics Ltd(CMMB)的股份？
截至2025Q4，共有30家机构持有Chemomab Therapeutics Ltd的股份，合计持有的股份价值约为390.31K，占公司总股份的17.98%。与2025Q3相比，机构持股有所增加，增幅为--。
哪个业务部门对Chemomab Therapeutics Ltd的收入贡献最大？
在--，--业务部门对Chemomab Therapeutics Ltd的收入贡献最大，创收--，占总收入的--%。
